Data collaborations with experts provide powerful real-world data
Published: November 15, 2022, 10:00 a.m. Updated: November 16, 2022, 10:04 a.m.MSD is convinced that real-world data is the way forward to better understand health problems and contribute to improved access to the most optimal treatment for patients.- Real-world data and real-world evidence help us fill critical evidence gaps that cannot be addressed using information from clinical trials. Data captured in healthcare can more effectively reflect heterogeneous patient populations where drugs are used in clinical practice, says Olivier Fouret, CEO MSD Sweden. He continues; – In addition, during the covid-19 pandemic, the eagerness to understand patient profiles and the spread of disease emphasized the importance of immediate and accessible real-world data. Reliable evidence from real-world data was critical in the intensive search for vaccination and effective treatments, as well as providing rapid insights to policy makers, policy makers, payers and providers.Eliminate cervical cancerThe first research of its kind, published in 2020, demonstrated the value of HPV vaccination using Swedish nationwide registries that collected population-level data over a 20-year period. – The results showed the significant relationship between HPV vaccination for preventive purposes in the prevention of cervical cancer [Lei et al]”, says Olivier Fouret. He continues; – In order to further review efficiency, safety and overall impact on public health, Sweden is now paving the way with a plan to eliminate cervical cancer. This approach is adapted to WHO’s global strategy for the elimination of cervical cancer.” Reference to article in Läkartidningen: The regions are charging to eradicate cervical cancer – Läkartidningen (lakartidningen.se) MSD in collaboration with KI, Karolinska InstitutetIn 2016, a formal partnership was established between MSD’s global research organization and Karolinska Institutet. – The collaboration has its basis in the unique Swedish data infrastructure with the possibility to cross-link data from different sources, together with the clinical and epidemiological expertise among researchers at Karolinska Institutet. Overlapping interest in diseases and epidemiology as well as methodological issues has resulted in numerous collaborations that deliver reliable data and support improved understanding of the impact of disease burden and the effects of drugs, says Oliver Fouret.Accurate quality measurement is essentialRobust, high-quality data sources are required to facilitate cross-functional learning among regulators, providers and patients regarding effectiveness relative to standard of care for different patient types and under different clinical conditions.- Reliable real-world data provide insights and improve our understanding of the burden of disease, treatment gaps, the impact of approved care pathways, adherence to guidelines, as well as healthcare performance and patient needs,” concludes Oliver Fouret. About MSDMSD, known as Merck & Co., Inc., Rahway, NJ, United States of America and Canada, is united in its purpose: We use the power of leading science to save and improve lives around the world. For more than a century, the company has been at the forefront of research, developing medicines, vaccines and innovative health solutions for the world’s most challenging diseases. MSD has its Sweden office in Hagastaden in Stockholm.www.msd.se The article is produced by Brand Studio in collaboration with MSD and not an article by Dagens industri
